Goldman Sachs Group Inc Seagen Inc. Call Options Transaction History

Goldman Sachs Group Inc

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 May 14, 2024	BUY	$191.51 - $216.16 $8.96 Million - $10.1 Million	46,800 New	46,800 $9.93 Million
Q3 2023 Nov 14, 2023	BUY	$191.51 - $216.16 $5.38 Million - $6.07 Million	28,100 Added 150.27%	46,800 $9.93 Million
Q2 2023 May 14, 2024	BUY	$187.64 - $206.25 $2.81 Million - $3.09 Million	15,000 Added 405.41%	18,700 $3.6 Million
Q2 2023 Aug 14, 2023	BUY	$187.64 - $206.25 $2.81 Million - $3.09 Million	15,000 Added 405.41%	18,700 $3.6 Million
Q1 2023 May 14, 2024	SELL	$127.59 - $203.08 $4.44 Million - $7.07 Million	-34,800 Reduced 90.39%	3,700 $749,000
Q1 2023 May 11, 2023	BUY	$127.59 - $203.08 $472,083 - $751,396	3,700 New	3,700 $749,000
Q2 2022 May 14, 2024	BUY	$108.81 - $179.33 $4.19 Million - $6.9 Million	38,500 New	38,500 $6.81 Million
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $5.28 Million - $8.7 Million	-48,500 Reduced 55.75%	38,500 $6.81 Million
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $10.4 Million - $13.7 Million	87,000 New	87,000 $12.5 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.